Insider · CIK 0001211781
Francois Heilbronn
Files at IPAR (INTER PARFUMS INC). First filing -, latest -.
In brief
Francois Heilbronn files SEC Form 4 as director at IPAR (INTER PARFUMS INC). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Francois Heilbronn has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 20 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 23, 2026 | IPAR INTER PARFUMS INC | MOption exercise Common Stock | +1,500 | $62.18 | $93k | 30,063 | Jan 26, 2026 |
| Jan 23, 2026 | IPAR INTER PARFUMS INC | MOption exercise Option-right to buyderivative | -375 | $0.00 | $0 | 0 | Jan 26, 2026 |
| Jan 23, 2026 | IPAR INTER PARFUMS INC | MOption exercise Option-right to buyderivative | -375 | $0.00 | $0 | 0 | Jan 26, 2026 |
| Jan 23, 2026 | IPAR INTER PARFUMS INC | MOption exercise Option-right to buyderivative | -375 | $0.00 | $0 | 0 | Jan 26, 2026 |
| Jan 23, 2026 | IPAR INTER PARFUMS INC | MOption exercise Option-right to buyderivative | -375 | $0.00 | $0 | 0 | Jan 26, 2026 |
| Dec 31, 2025 | IPAR INTER PARFUMS INC | AGrant or award Option-right to buyderivative | +300 | $0.00 | $0 | 300 | Jan 5, 2026 |
| Dec 31, 2025 | IPAR INTER PARFUMS INC | AGrant or award Option-right to buyderivative | +300 | $0.00 | $0 | 300 | Jan 5, 2026 |
| Dec 31, 2025 | IPAR INTER PARFUMS INC | AGrant or award Option-right to buyderivative | +300 | $0.00 | $0 | 300 | Jan 5, 2026 |
| Dec 31, 2025 | IPAR INTER PARFUMS INC | AGrant or award Option-right to buyderivative | +300 | $0.00 | $0 | 300 | Jan 5, 2026 |
| Dec 31, 2025 | IPAR INTER PARFUMS INC | AGrant or award Option-right to buyderivative | +300 | $0.00 | $0 | 300 | Jan 5, 2026 |
| Jan 27, 2025 | IPAR INTER PARFUMS INC | MOption exercise Common Stock | +1,500 | $69.11 | $104k | 28,563 | Jan 28, 2025 |
| Jan 27, 2025 | IPAR INTER PARFUMS INC | MOption exercise Option-right to buyderivative | -375 | $0.00 | $0 | 0 | Jan 28, 2025 |
| Jan 27, 2025 | IPAR INTER PARFUMS INC | MOption exercise Option-right to buyderivative | -375 | $0.00 | $0 | 0 | Jan 28, 2025 |
| Jan 27, 2025 | IPAR INTER PARFUMS INC | MOption exercise Option-right to buyderivative | -375 | $0.00 | $0 | 0 | Jan 28, 2025 |
| Jan 27, 2025 | IPAR INTER PARFUMS INC | MOption exercise Option-right to buyderivative | -375 | $0.00 | $0 | 0 | Jan 28, 2025 |
| Dec 31, 2024 | IPAR INTER PARFUMS INC | AGrant or award Option-right to buyderivative | +300 | $0.00 | $0 | 300 | Jan 3, 2025 |
| Dec 31, 2024 | IPAR INTER PARFUMS INC | AGrant or award Option-right to buyderivative | +300 | $0.00 | $0 | 300 | Jan 3, 2025 |
| Dec 31, 2024 | IPAR INTER PARFUMS INC | AGrant or award Option-right to buyderivative | +300 | $0.00 | $0 | 300 | Jan 3, 2025 |
| Dec 31, 2024 | IPAR INTER PARFUMS INC | AGrant or award Option-right to buyderivative | +300 | $0.00 | $0 | 300 | Jan 3, 2025 |
| Dec 31, 2024 | IPAR INTER PARFUMS INC | AGrant or award Option-right to buyderivative | +300 | $0.00 | $0 | 300 | Jan 3, 2025 |
Questions about Francois Heilbronn
Answered from the filings on this page, as of the latest one.
Is Francois Heilbronn buying or selling?
Francois Heilbronn has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Francois Heilbronn's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Francois Heilbronn has 0.
Where does Francois Heilbronn file Form 4?
Francois Heilbronn has filed Form 4 at IPAR (INTER PARFUMS INC). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.